Navigation Links
Regenesis Biomedical Announces Additions to Board of Directors
Date:8/22/2008

Strengthens breadth of experience and business expertise

SCOTTSDALE, Ariz., Aug. 22 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today the addition of two members to its Board of Directors. The two new directors are Peter G. Savas, Chairman and CEO of Alseres Pharmaceuticals, and Charles "Chuck" S. Lunden, a principal with Bederson and Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)

Peter Savas serves as Chairman and Chief Executive Officer of Alseres Pharmaceuticals. Prior to joining Alseres, Peter was Chairman and Chief Executive Officer of Aderis Pharmaceuticals, where he completed a $45 million private placement, strengthened the Board of Directors, Scientific Advisory Board and management team and rationalized the company's new product development partnerships. Peter holds his Bachelor of Arts degree in chemistry from Syracuse University.

Chuck Lunden is a Principal with Bederson and Company, certified public accountant consultants who provide financial and accounting services. He has comprehensive experience in corporate valuation and financial, tax and corporate management services. His designations include Certified Public Accountant, Accredited in Business Valuations, Certified Fraud Examiner, Certified Management Accountant, Chartered Life Underwriter, and Fellow of the Life Management Institute. Chuck holds a Bachelor of Science degree in economics from the University of Pennsylvania's Wharton School of Business. He is a member of the Board of Directors of HealthCare Data Diagnostics, a Medicare data analysis firm specializing in fraud detection. He is also a Member of the Board of Directors of the Spanish Health Ministries Inc.

"We are pleased to welcome these outstanding individuals to our team," said Virginia Rybski, Acting President of Regenesis. "Regenesis continues to demonstrate impressive revenue growth, and the perspectives of these individuals will contribute to our ongoing business plan execution."

About the Provant Wound Therapy System

Provant uses pulsed-radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative superficial soft tissues.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.

Contact: Regenesis Biomedical, Inc.

Scott Robey, Vice President Marketing

http://www.regenesisbiomedical.com 480-970-4970


'/>"/>
SOURCE Regenesis Biomedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
2. Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts
3. Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
4. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
5. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
6. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
7. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
8. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
9. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
10. HIPAA Privacy Rule Impedes Biomedical Research
11. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 ... ... has launched Rosalind™, the first-ever genomics analysis platform specifically designed for life ... Named in honor of pioneering researcher Rosalind Franklin, who made a major ...
(Date:10/11/2017)... NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic ... one eye at a time. So which eye do you rinse first if a dangerous ... have Plum Duo Eye Wash with its unique dual eye piece. , “Whether ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...
Breaking Biology Technology:
(Date:10/4/2017)... Oct. 4, 2017  GCE Solutions, a global clinical research organization ... document anonymization solution on October 4, 2017. Shadow is designed to ... comply with policy 0070 of the European Medicines Agency (EMA) in ... ... ...
(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
(Date:5/16/2017)... N.J. , May 16, 2017  Veratad Technologies, ... provider of online age and identity verification solutions, announced ... K(NO)W Identity Conference 2017, May 15 thru May 17, ... Regan Building and International Trade Center. ... the globe and in today,s quickly evolving digital world, ...
Breaking Biology News(10 mins):